Month: September 2025

OSLO, Norway (29 September 2025) – TGS, a global leader in energy data and intelligence, announces the commencement of a new multi-client Ultra-Long Offset Ocean Bottom Node (OBN) data acquisition campaign in the Gulf of America. The Amendment West-1 survey is TGS’ second campaign expanding multi-client node coverage in the Paleogene West play, adding more than 5,400 square kilometers within the East Breaks protraction area. Amendment West-1 will feature TGS’ Gemini™ enhanced frequency source and TGS’ ZXPLRe™ nodes. The Gemini source has been engineered to generate increased low-frequency energy for deep penetration and Full Waveform Inversion (FWI), while preserving high-frequency content necessary for conventional processing and imaging workflows.   The Amendment West-1 dataset, to be processed by TGS’ Imaging experts,...

Corbion hereby reports the transaction details related to its share buyback program announced on 1 September 2025. During the week of 22 September up to and including 26 September 2025 a total of 57.112 shares were repurchased at an average price of €16.756 for a total amount of €956,979.58 To date, the total consideration for shares repurchased amounts to €3,551,493.30 representing 35.51% of the overall share buyback program. Corbion publishes on a weekly basis every Monday, an overview of the progress of the share buyback program on its website: https://www.corbion.com/Investor-relations/shareholder-information This overview contains detailed information on the daily amount of repurchased shares and individual share purchase transactions.Attachment2025 SBB weekly update 202509026

Company AnnouncementGenmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDTCOPENHAGEN, Denmark; UTRECHT, The Netherlands; September 29, 2025, – Genmab A/S (Nasdaq: GMAB) and Merus N.V. (Nasdaq: MRUS) announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus, a clinical-stage biotechnology company with its late-stage breakthrough therapy asset petosemtamab, which is in Phase 3 development, for USD 97.00...

Next generation sustained-release formulations for a variety of peptides Executive summaryfirst biocompatible pharmaceutical formulations progress to preclinical models new sustained-release drug delivery platforms for peptides, melanocortins aim to predict drug release kinetics from new formulations liquid formulation allows flexible dosing through adjusting injection volumes perseverance during 10 years of in-house researchMELBOURNE, Australia, Sept. 28, 2025 (GLOBE NEWSWIRE) — CLINUVEL today announced that it is advancing new sustained-release liquid drug formulations in a preclinical program evaluating various drug release profiles. A decade of investment in fundamental research & development in CLINUVEL’s fully-owned Singaporean laboratories (VALLAURIX) has provided positive, consistent results demonstrating the potential...

Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: FX 4 Product Execution Plan Announced, will be the First Potential Model Under the FX Brand Designed for the Volume MarketFaraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: FX 4 Product Execution Plan Announced, will be the First Potential Model Under the FX Brand Designed for the Volume MarketFX Super One Middle East Final Launch event will be held on October 28, start of the first deliveries in the Middle East planned for November of this year. FF and FX will join WETEX 2025 in Dubai from September 30 to October 2, one of the largest and most influential exhibitions for sustainable and clean energy in the Middle East.LOS ANGELES, Sept. 28, 2025 (GLOBE NEWSWIRE) — Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday...

TOKYO and CAMBRIDGE, Mass., Sept. 28, 2025 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab) has been approved for once every four weeks intravenous (IV) maintenance dosing by the National Medical Products Administration (NMPA) in China. In January 2024, LEQEMBI was approved for the treatment of Alzheimer’s disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD) in China. After 18 months of a dosing regimen of 10 mg/kg once every two...

Conference call and webcast on Monday, September 29, 2025 at 8:00 am EDT BALA CYNWYD, Pa., Sept. 28, 2025 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host a conference call and webcast to discuss updates for the Company’s nomlabofusp clinical development program including data from the ongoing long-term open label study for the treatment of Friedreich’s ataxia on Monday, September 29, 2025 at 8:00 am EDT. Conference Call and Webcast DetailsTo access the webcast on Monday, September 29, 2025 at 8:00 am EDT, please visit this link to the event. To participate by phone, please dial 1-877-407-9716 (domestic) or 1-201-493-6779 (international) and refer to conference ID 13756144...

SAXONBURG, Pa., Sept. 28, 2025 (GLOBE NEWSWIRE) — Coherent Corp. (NYSE: COHR), a global leader in photonics, announced today that it will showcase its latest innovations in next-generation optical communications at ECOC 2025, taking place September 29-October 1 at the Bella Center in Copenhagen, Denmark (Booth #C3124). Coherent thought leaders will contribute to the Market Focus program through panels, workshops, and round table sessions. “ECOC is the European premier global stage for showcasing innovation in datacenters and communications, and we’re excited to demonstrate how in Coherent we are shaping next-gen optical networking. We are excited to be at ECOC showcasing our innovation, our portfolio and contributing to thought leadership. Through our advanced technologies, close industry collaborations, and broad portfolio, we...

VELA-1 and VELA-2 are two identical trials to evaluate the efficacy and safety of sonelokimab in adult participants with moderate to severe hidradenitis suppurativa (HS) and the first Phase 3 program using the higher clinical response level of HS Clinical Response (HiSCR) 75 as primary endpoint at week 16 Data was analyzed, as per protocol and in accordance with regulatory agency feedback, using a composite strategy as the primary analysis and a treatment policy strategy to test the robustness of the results: difference between the two methods relates to the statistical handling of intercurrent events In the combined VELA program, patients treated with sonelokimab experienced a clinically meaningful and statistically significant improvement across all primary and key secondary endpoints using both pre-specified strategies (p4, as well...

– By Month 1, numerically fewer cumulative events were observed with acoramidis compared to placebo – Acoramidis significantly reduced the cumulative risk of CVM or recurrent CVH through Month 30 versus placebo with a 49% hazard reduction (p